Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2019 Oct;21(5):e13134.
doi: 10.1111/tid.13134. Epub 2019 Jul 12.

Immunosuppression reduction in liver and kidney transplant recipients with suspected bacterial infection: A multinational survey

Daniel Shepshelovich  1   2 , Noam Tau  2   3 , Hefziba Green  2   4   5 , Benaya Rozen-Zvi  2   4 , Assaf Issaschar  2   6 , Marco Falcone  7 , Julien Coussement  8 , Oren Zusman  2   9 , Oriol Manuel  10 , Eytan Mor  2   11 , Julian Torre-Cisneros  12 , Dafna Yahav  2   13
Affiliations
Multicenter Study

Immunosuppression reduction in liver and kidney transplant recipients with suspected bacterial infection: A multinational survey

Daniel Shepshelovich et al. Transpl Infect Dis. 2019 Oct.

Abstract

Background: There is no consensus on the optimal management of immunosuppression during bacterial infections among solid organ transplant recipients.

Methods: A multicenter, cross-sectional survey, of high-volume kidney and liver transplant centers across US and Europe. Structured questionnaires including six multiple-choice questions concerning the management of immunosuppression during infection were distributed among 381 centers.

Results: A total of 124 (33%) centers fully completed the questionnaire: 67 liver, 57 kidney centers. Participating centers reported heterogenous approaches to immunosuppression management for all types of immunosuppressive drugs. Notably, kidney centers reported similar frequencies of either discontinuation (19%), continuation (19%), or dose reduction (17.5%) of antimetabolites; discontinuation only for life-threatening infection (17.5%) or case by case decisions (27%). Calcineurin inhibitors (CNI) management was heterogenous mostly among liver centers, with 8% discontinuing the CNI, 18% continuing, and 22% reducing dose. Heterogenous approaches to management of steroids and inhibitors of the mammalian target of rapamycin were also demonstrated.

Conclusions: Immunosuppression management during bacterial infection is heterogenous in US and European centers. Immunosupression reduction (ISR) during infection is a common practice, though supported by limited evidence. Demonstrating high heterogeneity in the approach to ISR, together with the equivocal results of clinical studies, support consideration of an interventional clinical trial.

Keywords: immunosuppression reduction; infection; kidney transplant; liver transplant.

PubMed Disclaimer

References

REFERENCES

    1. Briggs JD. Causes of death after renal transplantation. Nephrol Dial Transplant. 2001;16(8):1545-1549.
    1. The AST Infectious Disease Community of Practice. Amercian society of transplantation, infectious disease guidelines for transplantation. Am J Transpl. 2009;9(Suppl 4):S1.
    1. Cervera C, vanDelden C, Gavaldà J, et al. Multidrug-resistant bacteria in solid organ transplant recipients. Clin Microbiol Infect. 2014;20(Suppl-7):49-73.
    1. Hardinger K, Brennan DC. Maintenance immunosuppressive therapy in renal transplantation in adults. Marder S, ed. UpToDate. http://www.uptodate.com. (Accessed on December 01, 2017).
    1. Shih CJ, Tarng DC, Yang WC, Yang CY. Immunosuppressant dose reduction and long-term rejection risk in renal transplant recipientswith severe bacterial pneumonia. Singapore Med J. 2014;55(7):372-377.

Publication types

MeSH terms

Substances

LinkOut - more resources